| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communication |
Departments of Urology [F. J. M., A. S., C. Y. F. Y.], Biochemistry/Molecular Biology [F. J. M., A. S., C. Y. F. Y.], and Experimental Pathology [L. J.], Mayo Clinic/Foundation, Rochester, Minnesota 55905
Although a splicing variant of prostate specific antigen (PSA-v) mRNA has been described previously, whether its protein (PSA-v or PSA-related protein 1, i.e., PSA-RP1) is actually expressed in human prostate cells remains elusive. We report that PSA-v protein is expressed in prostatic epithelia of both cancerous and benign tissues. Also, secreted PSA-v can be detected in the medium of a prostate cancer (PCa) cell line. Consistently, PSA-v mRNA is exclusively expressed in benign luminal epithelia and cancer cells of the prostate by in situ hybridization. Northern analysis of a cohort of 51 pairs of RNA samples from microdissected tissues showed that PSA-v mRNA levels remained constant in both benign and cancerous tissues, whereas PSA levels declined in cancerous areas. Our result suggests that it would be feasible to develop proper immunoassays for PSA-v to test whether PSA-v could have some clinical utility.
This article has been cited by other articles:
![]() |
J. Groskopf, S. M.J. Aubin, I. L. Deras, A. Blase, S. Bodrug, C. Clark, S. Brentano, J. Mathis, J. Pham, T. Meyer, et al. APTIMA PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer Clin. Chem., June 1, 2006; 52(6): 1089 - 1095. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |